Related references
Note: Only part of the references are listed.Metastatic disease from uveal melanoma: treatment options and future prospects
Richard D. Carvajal et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Somatic mutation analysis in melanoma using targeted next generation sequencing
Allen P. Miraflor et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2017)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2017)
Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel
de Unamuno Bustos Blanca et al.
SCIENTIFIC REPORTS (2017)
Validation of an NGS mutation detection panel for melanoma
Anne Reiman et al.
BMC CANCER (2017)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Alan E. Siroy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
BRAF inhibitor activity in V600R metastatic melanoma
Oliver Klein et al.
EUROPEAN JOURNAL OF CANCER (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
